Stocks
Summit Therapeutics Sets November 14 FDA PDUFA Date for Ivonescimab
Summit Therapeutics has received a November 14 PDUFA date for its ivonescimab BLA. The company is also planning the HARMONi-3 PFS trial...
#pharmaceuticals 26 articles
Economy
Trump Imposes 100% Tariff on Generic Drugs, Sets 2028 US Production Deadline
President Donald Trump announced a 100% import duty on generic drugs from August 2028, giving manufacturers two years to move production to...
Stocks
FDA Clears Subcutaneous Leqembi Iqlik for At-Home Use
The FDA has approved Biogen and Eisai's Leqembi Iqlik, a subcutaneous version of their Alzheimer's treatment, for initiation and maintenance dosing, including...
Stocks
HHS, VA Memorandum Boosts Psychedelic Drugmakers
A new memorandum of understanding between HHS and the VA could significantly benefit companies developing psychedelic-based drug treatments for veterans.
Stocks
AbbVie’s Skyrizi Expands Pediatric Indication to Psoriatic Diseases
AbbVie's Skyrizi has received US FDA approval for children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This...
Stocks
Definium Therapeutics Prices $700M Public Offering
Definium Therapeutics announced the pricing of an upsized public offering, raising approximately $700 million in gross proceeds.
Stocks
FDA Greenlights uniQure’s AMT-130 Data for Accelerated Approval Filing
uniQure's stock surged after the FDA indicated that three-year Phase I/II data for its Huntington's disease gene therapy, AMT-130, could support an...
Stocks
Biogen Acquires RayThera for Up to $1 Billion, Bolstering Immunology Pipeline
Biogen Inc. announced an agreement to acquire private biotech RayThera Inc. for up to $1 billion, significantly expanding its immunology portfolio with...
Stocks
GSK, Incyte, OpenAI Lead Week’s Key Business Deals
Major transactions and discussions marked the week, with GSK, Incyte, Ingredion, and OpenAI among the notable players. Roku's potential sale also generated...